FDA priority review sets up Q3 verdict on rusfertide for polycythemia vera
Takeda and Protagonist's hepcidin mimetic faces an FDA decision built on Phase 3 VERIFY and Phase 2 REVIVE data, in a disease with no approved therapy that directly targets the mechanism driving red-cell overproduction.
Executive Summary
- The FDA is reviewing rusfertide under priority review, with a decision due before the end of the third quarter of 2026, on an application built from randomized Phase 3 and long-running Phase 2 evidence rather than early or surrogate data.
- Polycythemia vera patients today rely on phlebotomy and repurposed cytoreductive agents; rusfertide would be the first therapy built specifically around the hepcidin pathway that governs the disease's red-cell overproduction.
- The regulatory package draws on a Phase 3 trial that beat standard of care on its primary and all secondary endpoints, backed by four years of Phase 2 follow-up data and a tolerability profile dominated by injection-site reactions rather than more serious toxicity.
- The mechanism sits largely alone in this indication: most other polycythemia vera and adjacent myeloproliferative programs work through different pathways, leaving rusfertide's closest comparator as the sponsor's own follow-on study rather than a rival's.
The filing
The FDA accepted the New Drug Application for rusfertide and granted priority review on March 2, 2026, setting a PDUFA goal date in the third quarter of that year. Rusfertide also carries Breakthrough Therapy, Orphan Drug and Fast Track designations from the FDA. Andy Plump, Takeda's president of R&D, said the acceptance "brings us closer to potentially offering a first-in-class therapy that could meaningfully improve clinical outcomes and quality of life" for polycythemia vera patients. TakedaTakeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia VeraMar 2, 2026
What backs the application
The NDA rests primarily on the Phase 3 VERIFY study (NCT05210790), which met its primary endpoint and all four key secondary endpoints, and on four-year efficacy and safety data from the Phase 2 REVIVE study (NCT04057040). In VERIFY, patients on rusfertide plus standard of care showed a higher response rate than standard of care alone, covering hematocrit control, reduced phlebotomy need, and improved fatigue and symptom-burden scores. The most common adverse events through 52 weeks were injection site reactions (47.4%), anemia (25.6%) and fatigue (19.6%), mostly grade 1 or 2, with serious adverse events in 8.1% of rusfertide-treated patients. TakedaTakeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia VeraMar 2, 2026
The REVIVE precedent
REVIVE itself completed in 2024 with 70 patients randomized at 16 sites in the United States and India, and reported that a higher proportion of rusfertide-treated patients maintained hematocrit control without phlebotomy than those on placebo, 69.2% versus 18.5%, a result the trial's investigators called statistically significant. The trial's primary completion date moved across its life, from an original August 2022 target to October 2025 before the registry recorded a final primary completion date of February 2023, alongside enrollment growth from 30 to 70 patients as the study matured. NCT04057040Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)NCT04057040
The competitive field
Polycythemia vera's active pipeline is mechanistically diverse rather than crowded around hepcidin biology. Ruxolitinib and other JAK inhibitors, ropeginterferon alfa-2b, and Ono Pharmaceutical's TMPRSS6-targeted oligonucleotide sapablursen, now in Phase 3, work through different pathways entirely. The nearest direct comparator sharing rusfertide's target and modality is Takeda's own Phase 2 study of the drug in Japanese patients, still not yet recruiting, and Disc Medicine's DISC-3405, a hepcidin-pathway asset now in Phase 2. No competitor sharing rusfertide's Ferroportin target and mechanism class has yet reached a resolved Phase 3 outcome, leaving VERIFY as the first randomized test of hepcidin-pathway modulation to reach this stage in the disease.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.